Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Share-based Compensation (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Share-based Compensation for 13 consecutive years, with $783000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 155.88% to $783000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 7.36% increase, with the full-year FY2025 number at $1.5 million, up 7.36% from a year prior.
  • Share-based Compensation was $783000.0 for Q4 2025 at Ekso Bionics Holdings, up from $234000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $928000.0 in Q4 2022 to a low of $207000.0 in Q2 2025.
  • A 5-year average of $479000.0 and a median of $460000.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 301.16% in 2021, then plummeted 48.38% in 2023.
  • Ekso Bionics Holdings' Share-based Compensation stood at $791000.0 in 2021, then rose by 17.32% to $928000.0 in 2022, then tumbled by 48.38% to $479000.0 in 2023, then crashed by 36.12% to $306000.0 in 2024, then soared by 155.88% to $783000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Share-based Compensation are $783000.0 (Q4 2025), $234000.0 (Q3 2025), and $207000.0 (Q2 2025).